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Aim: To evaluate changes in indicators of endothelial function and their relationship with morphological forms of disease, stage 
of pathological process and tumor markers, by analysis the peripheral blood of lung cancer (LC) patients. Materials and Methods: 
38 LC patients without metastases (mean age — 57 years) prior chemo- and radiotherapy were included in the study. The duration 
of the disease manifestation was 18 months. 21% of patients had small cell LC, and the rest — non-small cell LC. The ratio of pa-
tients with stages IA, IB, IIA, IIB, IIIA and IIIB LC was 1 : 3 : 3 : 4 : 4 : 4. The enzyme immunoassay, spectrophotometry, and 
statistical data analysis were used. Results: Endothelial dysfunction of vessels was characterized by increased blood levels of vas-
cular endothelial growth factor (VEGF), endothelin-1 (ET1), homocysteine (HCys), cyclic guanosine monophosphate (cGMP), 
P-selectin (PSel) and nitrites (NO2) and simultaneously by decreased values of prostacyclin (PgI2). Those were observed in 100; 
90; 76; 71; 50; 53 and 79% of LC cases, respectively. Disturbances of vascular endothelial function were associated with pa-
tient’s age, disease duration, and morphological form and LC stage. Such changes were observed in women with higher prevalence. 
The studied indices correlated with tumor markers, namely transforming growth factor beta (TGFβ1), fibronectin and osteopontin. 
Conclusion: Indices of vascular endothelial dysfunction in LC can be of diagnostic and prognostic value.
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Lung cancer (LC) occupies the first place in the 
structure of cancer morbidity in men and it is one of the 
leading causes of cancer mortality [4, 9]. The inci-
dence of LC in the male population of various countries 
(including Ukraine) is more than 60 per 100 000, in the 
female population — 14–30 per 100 000, and in many 
countries these values increase annually [8, 25]. Every 
fourth man from newly registered cancer patients and 
every third of those cancer patients who died are the 
LC patients, as discussed in [16].
Tumor endothelial cells differ significantly from 
normal endothelial cells by structural and functional 
characteristics that finally determine the process 
of angioneogenesis [22]. Changes of expression pat-
tern of the proteins controlling angiogenesis can serve 
as prognostic marker of malignant process [26]. They 
can be used also for monitoring of anticancer treat-
ment efficacy in LC patients [3]. In particular, in case 
of lung tissue damage, the endothelial system reacts 
first; drastic increase of the blood level of vasocon-
strictor endothelin-1 (ET1) is considered as a marker 
of activity of destruction process.
Vascular endothelial growth factor (VEGF) plays the 
leading role among tumor angioneogenesis regulators. 
It is essential for prognosis of a course of malignant 
di sease [6], for staging and the rate of metastasis 
of LC [15]. The direct correlation between VEGF levels 
in blood and tumor size is evidenced [19]. It should 
be noted that high levels of VEGF in serum are associ-
ated with low survival rates in patients with non-small 
cell LC [2].
Disorders in cell-to-cell adhesion are typical for 
many malignant tumors [18]. Proteins controlling this 
process in association with vascular endothelium are 
involved into LC pathogenesis [13]. The imbalance 
of E- and P-selectin (ESel, PSel) enhances dissemina-
tion of tumor cells [10]. The excess of selectin in cul-
ture medium was accompanied by increased adhesion 
of tumor cells to endothelial cells [7].
Many questions concerning functional state of en-
dothelial blood vessels (FSVE) in LC are still unans-
wered. For example, it is not clear how the changes 
of ration between vasoconstrictors and vasodilators, 
measured in blood and occurs, and its relationship 
to other tumor markers remains undefined [1, 20].
The aim and the objectives of this study were the 
assessment of FSVE variations (VEGF, ET1, ESel, PSel, 
TxA2, HCys, PgI2, NO2, cGMP) in blood of LC patients, 
as well as their association with morphological forms 
of the disease, pathological process stage and the 
tumor markers (transforming growth factor — TGFβ1, 
fibronectin — FN, osteopontin — OP).
MATERIALS AND METHODS
38 LC patients without metastases (35–76 years; 
average 56.6 ± 1.88 years), prior chemo- and/or radio-
therapy, were included into the study. 29 (76%) patients 
were men and 9 (24%) patients— women (who were 
on average 10 years older; χ2 = 2.23; p = 0.032). The du-
ration of the LC manifestation was 17.9 ± 1.29 months. 
21% of patients had small cell LC, and the rest 79% — 
non-small cell LC. The ratio of IA, IB, IIA, IIB, IIIA and 
IIIB LC stages was 1 : 3 : 3 : 4 : 4 : 4, respectively. With 
regard to LC morphological forms and stage there was 
no differences between genders. The control group 
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consisted of 30 healthy persons (17 men and 13 women, 
average age 41.1 ± 6.1 years; р > 0.05).
The following methods was used for diagnostic: 
X-ray, computed or magnetic resonance tomography 
of the lungs (“Multix-Compact-Siemens”, Germany; 
“Somazom-Emotion-6-Siemens”, Germany; “Gy-
goscan-Intera-Philips”, The Netherlands). Enzyme 
immunoassay (reader “PR2100-Sanofi Diagnostic 
Pasteur”, France) was performed for determination 
of VEGF, ET1, TxA2, HCys, PgI2, cGMP, ESel, PSel, 
TGFβ1, FN and OP (kits “R&D-Systems”, USA, “DRG”, 
USA, “Amercham”, United Kingdom, “IBL”, Germany, 
“Immundiagnostik”, Germany, “ProCon”, Russia). 
Blood NO2 levels were determined by spectrophoto-
metry (“SF46”, Russia), using Grace reagent.
Statistical analysis of the obtained results was car-
ried out, using ANOVA/MANOVA dispersion analysis 
(programs “Microsoft Excel” and “Statistica-Stat-
Soft”, USA). Mean values (M), standard deviations (SD) 
and the errors (m), correlation coefficients (r), criteria 
of regression (R), dispersion (D), the t-Studient (t), the 
Wilcoxon — Rao (WR), MacNemar — Fisher (χ2) and 
the statistical significance (p) were calculated, using 
abovementioned programs.
RESULTS AND DISCUSSION
Blood levels of VEGF are 90.0 ± 5.5 pg/ml, ET1 — 
4.0 ± 0.1 pg/ml, TxA2 — 8.0 ± 1.6 ng/ml, HCys — 
9.3 ± 0.6 mmol/l, PgI2 — 72.6 ± 9.0 ng/ml, NO2 — 5.1 ± 
0.1 mmol/l, cGMP — 11.2 ± 0.2 pmol/ml, ESel — 241.6 ± 
12.9 ng/ml, PSel — 40.8 ± 1.6 ng/ml in healthy indi-
viduals. The increases of VEGF (t = 16.82, p < 0.001) 
by 4.7 fold, ET1 (t = 9.00, p < 0.001) by 1.9 fold, 
HCys (t = 7.69, p < 0.001) by 68%, cGMP (t = 4.89, 
p < 0.001) by 23%, PSel (t = 3.52, p = 0.001) by 17% 
and NO2 (t = 2.43, p = 0.018) by 12%, which were ac-
companied by PgI2 values decrease (t = 6.73, p <0.001) 
by 75%, in LC patients (Fig. 1). These changes (< M ± 
SD > healthy) were found in 100; 90; 76; 71; 50; 53 and 
79% of LC patients, respectively (Fig. 2).
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Fig. 1. Variations of FSVE indices in LC patients
Notes: the changes degrees were calculated in % to indices 
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Fig. 2. Deviation rate (%) for each FSVE index in LC patients 
from those of healthy individuals (100%)
As evidenced by statistical analysis, the LC mor-
phological forms is associated with TxA2 level (D = 2.08, 
p = 0.047), and the disease stage affects the blood 
levels of ET1 (D = 2.44, p = 0.038) and NO2 (D = 3.73, 
p = 0.009). Regression analysis showed the direct 
ET1 (R = +2.39, p = 0.024) and cGMP (R = +2.09, p = 0.046) 
patient’s age-dependence, HCys (R+ = 2.12, 
p = 0.044) disease duration-dependence, and VEGF 
(R = +2.53, p = 0.017) and ET1 (R = +2.19, p = 0.037) 
process pathological stage-dependence.
According to multifactor Wilcoxon — Rao analysis, 
only gender of the LC patients influences the integral 
state of FSVE (WR = 3.50, p = 0.005). In the women 
group such indices as VEGF (t = 2.13, p = 0.040) 
ET1 (t = 2.61, p = 0.013) and ESel (t = 4.54, p < 0.001) 
were significantly higher (20; 28 and 24%, respec-
tively).
In patients with non-small cell LC the PSel values 
were 22% higher (t = 3.39, p = 0.002). Moreover, 
in these patients the values of NO2 (t = 2.86, p = 0.008) 
and PSel (t = 5.74, p < 0.001) differed significantly from 
the levels in healthy individuals, such shifts were not 
observed in patients with small cell LC.
Concerning PSel, special comments should 
be made. The partial delay of leukocytes with incom-
plete “stop” on the endothelial surface (rolling) is go-
ing on under the control of the adhesive protein PSel 
(CD62+). After endothelium stimulation (by thrombin, 
histamine, reactive oxidized substances, etc.) the PSel 
is rapidly translocated on the surface of endothelial cell. 
At LC, the PSel is most probably involved in mediating 
leukocyte adhesion to activated endothelium upon 
the cancerose inflammation. The soluble form of PSel 
in blood of LC patients is the product of proteolysis and, 
most likely, in this fragment the transmembrane domain 
is absent. The observed PSel increase in patients with 
non-small cell LC may be due to excessive accumula-
tion of neutrophils on the endothelial surface, which 
occurs also in other lung diseases (acute pneumonia, 
respiratory distress syndrome). Importantly, the malig-
nant cells of LC patients may express the PSel recep-
tors, suggesting that the PSel plays a specific role in the 
formation of both, tumor and metastases.
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TGFβ1, FN and OP are considered as LC mar-
kers. Their levels in blood of LC patients were 411.9 ± 
12.48 ng/ml, 742.7 ± 7.50 g/ml, and 40.4 ± 1.13 ng/ml, re-
spectively. These values are significantly higher (p < 0.001) 
compared with healthy individuals (7.8 times (t = 25.50), 
10% (t = 6.13) and 90% (t = 12.54)). It is known that 
the increased levels of TGF1β cytokine in blood upon 
tumor growth indicate the activation of mechanisms 
of immune suppression [12]. Upon tumor progression 
in LC patients the TGF1β indices are elevated [23]. 
In the endothelial cells of LC patients TGFβ1 promotes 
α2-glycoprotein synthesis that will result in protection 
of tumor cells from apoptosis [21].
In LC patients FN serves as activator of tumor associ-
ated gelatinases (matrix metalloproteinase 2 and 9) [5], 
besides, concentrations of these matrix proteins are 
increased both, in blood and in tumor surrounding tis-
sues [17]. Herewith in LC patients the FN level may serve 
as neoangiogenesis marker, at least partially [24]. In neo-
angiogenesis process along with VEGF, proinflamma-
tory cytokine OP takes part, which is believed to display 
unfavorable course of LC [15, 19]. The OP level in blood 
is associated directly with metastatic disease and with 
high progression rates in LC patients [11, 14].
In LC patients the specific correlations between stu-
died markers were found (Fig. 3). The FN level correlated 
directly with indices of VEGF (r = +0.620, p <  0.001), 
PgI2 (r = −0.619, p < 0.001) and ESel (r = +0.483, 
p = 0.002). Moreover, the TGFβ1 correlated directly with 
VEGF (r = +0.352, p = 0.030) and inversely with PSel 
(r = 0.378, p = 0.019). The OP levels correlated positively 
with HCys (r = +0.331, p = 0.043). Hence, there are the 
close interconnections between tumor markers and pro-
teins that determine FSVE in LC patients. The presented 
data might result in a set of prognosrtic markers.
CONCLUSIONS
LC is characterized by vascular endothelial dys-
function which is manifested in enhanced blood levels 
of VEGF, ET1, HCys, cGMP, PSel and NO2 and reduced 
PgI2 values, and is observed in 100; 90; 76; 71; 50; 
53 and 79% LC patients, respectively. In LC patients 
the FSVE disorders are associated with patient age 
(ET1, cGMP), disease duration (HCys), morphological 
form (TxA2) and disease stage (VEGF, ET1, PSel, NO2) 
with the higher prevalence in women. Such indices, 
as VEGF, PgI2, and ESel correlate with tumor markers 
(TGFβ1, FN, OP), displaying interrelations of these 
proteins in LC pathogenesis. These changes may 
be the valuable prognostic markers.
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